Market Closed -
Warsaw S.E.
11:55:50 2024-04-26 EDT
|
5-day change
|
1st Jan Change
|
1.02
PLN
|
-0.49%
|
|
-0.97%
|
+9.91%
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Capitalization
1 |
41.5
|
31.65
|
20.66
|
73.36
|
60.12
|
20.83
|
Enterprise Value (EV)
1 |
36
|
27.15
|
19.28
|
63.47
|
56.41
|
20.83
|
P/E ratio
|
-20.6
x
|
-13.5
x
|
-13.4
x
|
-14.1
x
|
-6.01
x
|
-24.8
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
157
x
|
102
x
|
39.9
x
|
107
x
|
122
x
|
149
x
|
EV / Revenue
|
137
x
|
87.4
x
|
37.2
x
|
92.3
x
|
115
x
|
149
x
|
EV / EBITDA
|
-18.4
x
|
-11.6
x
|
-11.6
x
|
-19.8
x
|
-18.7
x
|
43.7
x
|
EV / FCF
|
-2.96
x
|
-3.05
x
|
-5.02
x
|
-15.7
x
|
-28.1
x
|
-
|
FCF Yield
|
-33.7%
|
-32.8%
|
-19.9%
|
-6.35%
|
-3.55%
|
-
|
Price to Book
|
3.24
x
|
2.23
x
|
1.68
x
|
4.16
x
|
7.77
x
|
-
|
Nbr of stocks (in thousands)
|
12,970
|
12,970
|
13,957
|
16,748
|
16,748
|
16,748
|
Reference price
2 |
3.200
|
2.440
|
1.480
|
4.380
|
3.590
|
1.244
|
Announcement Date
|
18-05-02
|
19-05-03
|
20-05-29
|
21-04-30
|
22-05-04
|
23-04-28
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net sales
1 |
0.2635
|
0.3108
|
0.5177
|
0.6875
|
0.4925
|
0.1395
|
EBITDA
1 |
-1.961
|
-2.35
|
-1.661
|
-3.207
|
-3.023
|
0.4772
|
EBIT
1 |
-2.015
|
-2.405
|
-1.709
|
-3.264
|
-3.074
|
0.415
|
Operating Margin
|
-764.56%
|
-773.94%
|
-330.12%
|
-474.76%
|
-624.12%
|
297.4%
|
Earnings before Tax (EBT)
1 |
-2.035
|
-2.423
|
-1.538
|
-5.244
|
-10.69
|
-0.7835
|
Net income
1 |
-2.013
|
-2.345
|
-1.536
|
-5.189
|
-10.01
|
-0.8386
|
Net margin
|
-764.01%
|
-754.37%
|
-296.71%
|
-754.79%
|
-2,031.6%
|
-600.93%
|
EPS
2 |
-0.1552
|
-0.1808
|
-0.1101
|
-0.3098
|
-0.5974
|
-0.0501
|
Free Cash Flow
1 |
-12.15
|
-8.913
|
-3.841
|
-4.032
|
-2.004
|
-
|
FCF margin
|
-4,610.21%
|
-2,867.74%
|
-741.9%
|
-586.43%
|
-406.98%
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
18-05-02
|
19-05-03
|
20-05-29
|
21-04-30
|
22-05-04
|
23-04-28
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
5.51
|
4.49
|
1.37
|
9.88
|
3.71
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-12.1
|
-8.91
|
-3.84
|
-4.03
|
-2
|
-
|
ROE (net income / shareholders' equity)
|
-15.1%
|
-16.3%
|
-11.3%
|
-33.1%
|
-78.7%
|
-12.1%
|
ROA (Net income/ Total Assets)
|
-5.99%
|
-6.06%
|
-4.09%
|
-7.23%
|
-7.63%
|
-
|
Assets
1 |
33.62
|
38.71
|
37.55
|
71.75
|
131.1
|
-
|
Book Value Per Share
2 |
0.9900
|
1.100
|
0.8800
|
1.050
|
0.4600
|
-
|
Cash Flow per Share
2 |
0.4300
|
0.3500
|
0.1400
|
0.6200
|
0.2400
|
-
|
Capex
1 |
5.82
|
0.06
|
0.04
|
0.15
|
0.05
|
0.01
|
Capex / Sales
|
2,206.83%
|
18.03%
|
7.01%
|
21.43%
|
10.16%
|
6.03%
|
Announcement Date
|
18-05-02
|
19-05-03
|
20-05-29
|
21-04-30
|
22-05-04
|
23-04-28
|
|
1st Jan change
|
Capi.
|
---|
| +9.91% | 5.06M | | +1.51% | 42.75B | | +49.22% | 41.61B | | +8.57% | 41.34B | | -12.36% | 26.59B | | +8.92% | 25.49B | | -25.13% | 18.12B | | +29.17% | 12.24B | | -3.12% | 11.76B | | +6.35% | 11B |
Other Biotechnology & Medical Research
|